Bali Zero
  • Home
  • Visa
  • Tax
  • Property
Get Started
KBLI Navigator/Section C/21014
KBLI 21014

Veterinary Pharmaceutical Raw Material Manufacturing

Industri Bahan Baku Farmasi untuk Hewan

🏭 Section C — Manufacturing

PMA status not yet verified for this KBLI 2025 code

❓PMA unverifiedMedium-High RiskDirect Match✓OSS-verified · KBLI 2025

Kelompok ini mencakup pembuatan dan pengolahan bahan obat, bahan pembantu untuk hewan, yang berasal dari bahan kimia, bahan alam, hewan dan tumbuh-tumbuhan termasuk yang berasal dari hasil biologis, seperti bahan obat-obatan, seperti antisera dan fraksi darah lainnya, vaksin dan preparat homeopatik, substansi aktif obat untuk bahan farmakologi dalam pembuatan obat-obatan, seperti antibiotik, vitamin, salisilik dan asam o-asetilsalsilik, pengolahan darah, gula murni kimia, garam farmasi, pengolahan kelenjar, dan ekstraksi kelenjar.

Licensing Overview
Risk LevelMenengah Tinggi
License TypeNIB + Sertifikat Standar
Foreign OwnershipNot verified — confirm in OSS
Processing7 working days
Authoritative BPS crosswalk
Official BPS 2020 → 2025 crosswalk ancestors: 21014

Source: the BPS 2020↔2025 conversion table, mechanically extracted and acceptance-gate verified. It shows which 2020 codes map to this 2025 code — provenance only, not a licensing claim: the regulatory regime of these predecessor codes has not been adjudicated as transferring.

PP 28/2025 licensing source
PP 28/2025 licensing-source codes (KBLI 2020 numbering): 21014

These codes identify the PP 28/2025 regulatory rows used as licensing sources for this page. They are not the official BPS 2020 → 2025 crosswalk and do not establish predecessor ancestry.

Sources & Verification

Each data layer below traces to a government source with its KBLI vintage — or is declared as a gap. Nothing in these layers is silently filled in.

Activity definition
BPS Peraturan 7/2025 + PP 28/2025VerifiedKBLI 2025

Title and scope as defined by the KBLI-2025 classification.

locator: OSS_RBA_2025_id_version_fff4053d

Risk & licensing
OSS RBA risk scope (ruang lingkup)VerifiedKBLI 2025

Risk category and licensing rows are KBLI-2025-native from the OSS Risk-Based Approach catalog.

locator: OSS_RBA_resiko_2025

Foreign ownership (PMA)
No adjudicated per-code official basisDeclared gap—

The canonical record declares a verification gap for the current ownership value. The instrument locator layer can identify a potentially applicable provision, but it does not verify this whole-code verdict; confirm it at oss.go.id before relying on it.

Dataset last updated 2026-08-15 · KBLI 2020 and KBLI 2025 reuse code numbers for different activities — cross-vintage rows are labeled, never merged silently.

Common Questions
Can foreigners operate a veterinary pharmaceutical raw material manufacturing business in Indonesia?
Not yet verified. The canonical record carries a current PMA label for KBLI 21014 (Industri Bahan Baku Farmasi untuk Hewan), but no adjudicated per-code official basis and source vintage verify that whole-code verdict. Confirm the current treatment at oss.go.id before planning a PT PMA. (No adjudicated per-code official basis and vintage currently verify this verdict; confirm it at oss.go.id before relying on it.)
What license is required for KBLI 21014?
KBLI 21014 has a Menengah Tinggi risk classification. Required license: NIB + Sertifikat Standar. Processing time: 7.
What is KBLI 21014?
KBLI 21014 is the Indonesian business classification code for "Industri Bahan Baku Farmasi untuk Hewan" (Veterinary Pharmaceutical Raw Material Manufacturing). It falls under Section C of KBLI 2025, the Indonesian Standard Industrial Classification updated by BPS (Regulation 7/2025). The June 2026 KBLI 2025 transition window has closed; operators should verify the code's current OSS/NIB treatment before relying on it for licensing, reporting, or amendments.
How did KBLI 21014 change from KBLI 2020 to 2025?
According to the official BPS 2020 → 2025 crosswalk, KBLI 21014 has recorded KBLI 2020 ancestor(s) 21014. This is provenance only, not a licensing claim; no predecessor licensing regime is asserted to transfer. The June 2026 KBLI 2025 transition window has closed. If an NIB still relies on legacy KBLI 2020 mappings, treat the migration as overdue and verify/remediate the OSS record before new license applications, amendments, LKPM, import approvals, or investor/worker sponsorship.

Related Codes

21015Section C

Medical Diagnostics, Bandages & Health Support Devices

Industri Alat Diagnosis Medis, Perban, Kasa, dan Penunjang Kesehatan Lainnya

→
❓PMA unverifiedHigh Risk
21013Section C

Veterinary Pharmaceutical Product Manufacturing

Industri Produk Farmasi untuk Hewan

→
❓PMA unverifiedMedium-Low Risk
21021Section C

Herbal Medicine Raw Material Manufacturing, Human

Industri Bahan Baku Obat Bahan Alam untuk Manusia

→
🏝️✅Registrable in Bali🚫Closed· 0% foreign ownershipHigh Risk
21012Section C

Human Pharmaceutical Product Manufacturing

Industri Produk Farmasi untuk Manusia

→
❓PMA unverifiedHigh Risk
21022Section C

Herbal Medicine Product Manufacturing, Human

Industri Produk Obat Bahan Alam untuk Manusia

→
🏝️✅Registrable in Bali🚫Closed· 0% foreign ownershipHigh Risk
21011Section C

Human Pharmaceutical Raw Material Manufacturing

Industri Bahan Baku Farmasi untuk Manusia

→
❓PMA unverifiedHigh Risk
📋

Ready to register this business?

Bali Zero can verify PMA eligibility before company setup, KBLI registration, NIB, and licensing for KBLI 21014.

Virtual Office

IDR 5.000.000

Legal address options after eligibility verification

5,000+ companies registered since 2020

Get started on WhatsApp
5k+
Clients
★ 4.9
Rating
693
Google reviews
Talk on WhatsApp
Zantara AIOSS Intelligence System
Context21014
Ask me about KBLI 21014: its official scope, licensing, risk, or foreign-ownership verification.